Currently, NCCN guidelines state that for multi-visceral resection in primary GIST, imatinib may be beneficial as neoadjuvant therapy [19]. Similarly, the ESMO recommends neoadjuvant imatinib in patients with localized disease if it results in less extensive surgery and a lower risk of tumor rupture and bleeding [19]. Neoadjuvant therapy typically involves a daily dose of 400 mg; however, for cases with a KIT exon 9 mutation, an increased dose of 800 mg is recommended. This evidence concerns the gene KIT and gastrointestinal stromal tumor.